Tumour lysate particle loaded dendritic cell vaccine - Elios Therapeutics

Drug Profile

Tumour lysate particle loaded dendritic cell vaccine - Elios Therapeutics

Alternative Names: TL + YCWP + DC; TL-YCWP-DC; TLPLDC

Latest Information Update: 18 Mar 2016

Price : $50

At a glance

  • Originator Orbis Health Solutions
  • Developer Cancer Insight; Orbis Health Solutions
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Malignant melanoma
  • Clinical Phase Unknown Solid tumours

Most Recent Events

  • 23 Dec 2014 Phase-II/III clinical trials in Malignant melanoma (Late-stage disease, Metastatic disease, Adjuvant therapy) in USA (Intradermal) (NCT02301611)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top